Professor Rosanna Peeling is the Chair of Diagnostics Research at the London School of Hygiene and Tropical Medicine (LSHTM) and founder and Director of the International Diagnostics Centre (IDC) where she facilitates the development and evaluation of point-of-care tests for the detection of multiple diseases.

Trained as a medical microbiologist, Prof. Peeling was the Research Coordinator and Head of Diagnostics Research at the UNICEF/UNDP/World Bank/WHO Special Programme on Research and Training in Tropical Diseases (WHO/TDR) in Geneva, Switzerland, and the Chief of the Canadian National Laboratory for Sexually Transmitted Diseases before assuming her current position at LSTHM.

For the first two years at WHO, Prof. Peeling was in charge of the STD Diagnostics Initiative (SDI) which aimed to facilitate the development and evaluation of point-of-care tests for sexually transmitted infections (STIs). Over the subsequent years, her work in WHO broadened to include diagnostic development and evaluation for diseases of poverty. She also led multi-country implementation research to inform country policy decisions on adoption of novel diagnostic tests. Prof. Peeling was funded by the Bill & Melinda Gates Foundation to evaluate the performance and utility of rapid syphilis tests in increasing access to prenatal screening and prevent stillbirths and congenital syphilis. Her team worked in seven countries to develop strategies and tools for the introduction of rapid tests, including the development of comprehensive systems to ensure the quality of tests and testing being performed outside of laboratory settings.

Prof. Peeling’s work at LSHTM spans from facilitating test development and evaluation to translation of evidence to policy, appropriate placement of new diagnostic technologies into different healthcare settings to ensure maximum impact, and innovation in the uptake of testing by marginalised populations. She established the IDC to provide a global hub for advocating the value of diagnostics, fostering innovation, and accelerating regulatory approval and access to quality-assured diagnostics to improve global health.